Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bone Biologics CorpBBLG · Entity 8560 | Director | September 28, 2026 | September 30, 2026 |
| HARVARD BIOSCIENCE INCHBIO · Entity 7369 | Director | June 09, 2026 | June 11, 2026 |
| Opus Genetics, Inc.IRD · Entity 5892 | Chief Financial Officer | September 03, 2026 | September 08, 2026 |
| PURPLE BIOTECH LTD.PPBT · Entity 8457 | Director | March 18, 2026 | March 18, 2026 |
| Verastem, Inc.VSTM · Entity 5242 | Director | December 16, 2025 | December 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bone Biologics Corp
Report date September 28, 2026 · Filed September 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2036-09-28 | Direct | 113,896 |
Reported balance
After 2026-09-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-28 · Grant · Acquired 113,896 · Balance 113,896 F1: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments. |
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.28 · Expires 2035-06-04 | Direct | 10,483 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 10,483 F2: This option is fully exercisable as of the date of this report. |
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.38 · Expires 2034-09-17 | Direct | 5,119 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 5,119 F2: This option is fully exercisable as of the date of this report. |
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $25.44 · Expires 2034-01-08 | Direct | 2 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 2 F2: This option is fully exercisable as of the date of this report. |
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $25.44 · Expires 2034-01-08 | Direct | 1,335 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 1,335 F2: This option is fully exercisable as of the date of this report. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments.
F2: This option is fully exercisable as of the date of this report.
HARVARD BIOSCIENCE INC
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,556 |
Reported balance
After 2026-06-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 16,556 · Balance 27,556 F1: Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier. F2: Includes (a) the award described in footnote (1) above and (b) 11,000 shares of common stock beneficially owned by the Reporting Person. F3: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and are beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.
F2: Includes (a) the award described in footnote (1) above and (b) 11,000 shares of common stock beneficially owned by the Reporting Person.
F3: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and are beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.
Opus Genetics, Inc.
Report date September 03, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 556,375 |
Reported balance
After 2026-09-03 transaction · row 1
1 source rowRow 1 · 2026-09-03 · Sale · Disposed 28,000 · Balance 556,375 F1: A portion of the shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Issuer, to satisfy tax withholding obligations that arose in connection with the vesting and settlement of restricted stock units, and the remainder of the shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 30, 2026. The Rule 10b5-1 trading plan is a pre-arranged written trading plan pursuant to which shares of the Issuer's common stock are sold automatically based on a predetermined formula that was established by the Reporting Person at a time when the Reporting Person was not aware of any material nonpublic information about the Issuer. F2: The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $4.29 to $4.79, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: A portion of the shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Issuer, to satisfy tax withholding obligations that arose in connection with the vesting and settlement of restricted stock units, and the remainder of the shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 30, 2026. The Rule 10b5-1 trading plan is a pre-arranged written trading plan pursuant to which shares of the Issuer's common stock are sold automatically based on a predetermined formula that was established by the Reporting Person at a time when the Reporting Person was not aware of any material nonpublic information about the Issuer.
F2: The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $4.29 to $4.79, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
PURPLE BIOTECH LTD.
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 3,062,500 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 3,062,500 F1: Includes 2,454,167 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: Represents stock option to purchase 112,500 Ordinary Shares (equivalent to 56 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $0.146765625 per Ordinary Share and the option expires on December 29, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: Represents stock option to purchase 300,000 Ordinary Shares (equivalent to 150 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 274,997 Ordinary Shares are vested and exercisable, with the remaining options to purchase 25,003 Ordinary Shares vesting in equal quarterly installments until April 24,2026.The exercise price of this stock option is $0.059375 per Ordinary Share and the option expires on April 24, 2028. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: Represents stock option to purchase 2,650,000 Ordinary Shares (equivalent to 1,325 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 220,833 Ordinary Shares are vested and exercisable, with the remaining options to purchase 2,429,167 Ordinary Shares vesting in equal quarterly installments until October 21, 2029.The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 2,454,167 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares
F2: Represents stock option to purchase 112,500 Ordinary Shares (equivalent to 56 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $0.146765625 per Ordinary Share and the option expires on December 29, 2026.
F3: Represents stock option to purchase 300,000 Ordinary Shares (equivalent to 150 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 274,997 Ordinary Shares are vested and exercisable, with the remaining options to purchase 25,003 Ordinary Shares vesting in equal quarterly installments until April 24,2026.The exercise price of this stock option is $0.059375 per Ordinary Share and the option expires on April 24, 2028.
F4: Represents stock option to purchase 2,650,000 Ordinary Shares (equivalent to 1,325 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 220,833 Ordinary Shares are vested and exercisable, with the remaining options to purchase 2,429,167 Ordinary Shares vesting in equal quarterly installments until October 21, 2029.The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030.
Verastem, Inc.
Report date December 16, 2025 · Filed December 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,678 |
Reported balance
After 2025-12-16 transaction · row 1
1 source rowRow 1 · 2025-12-16 · Sale · Disposed 283 · Balance 41,678 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 28, 2026 Filed Sep 30, 2026 21:14 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantNon-Employee Stock Option · Derivative | 113,896 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001493152-26-045149 · ownership.xml · derivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,896 Underlying: Common Stock · 113,896 shares Expires 2036-09-28 F1 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments. Read SEC document |
| September 03, 2026 Filed Sep 8, 2026 20:05 UTC | Opus Genetics, Inc. IRD · Entity 5892 | SaleCommon Stock | 28,000 | $4.54 | $127,212.40 |
DisclosureSEC source: 0001140361-26-035912 · form4.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 556,375 F1 · kind: A portion of the shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Issuer, to satisfy tax withholding obligations that arose in connection with the vesting and settlement of restricted stock units, and the remainder of the shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 30, 2026. The Rule 10b5-1 trading plan is a pre-arranged written trading plan pursuant to which shares of the Issuer's common stock are sold automatically based on a predetermined formula that was established by the Reporting Person at a time when the Reporting Person was not aware of any material nonpublic information about the Issuer. F2 · price: The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $4.29 to $4.79, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 23, 2026 Filed Jul 27, 2026 20:06 UTC | Opus Genetics, Inc. IRD · Entity 5892 | SaleCommon Stock | 7,783 | $2.95 | $22,941.95 |
DisclosureSEC source: 0000905148-26-003351 · form4.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 584,375 F1 · kind: The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person. F2 · price: The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $2.9006 to $3.025, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 14:02 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 16,556 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-26-004057 · ownership.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,556 F1 · shares: Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier. F2 · balance_after: Includes (a) the award described in footnote (1) above and (b) 11,000 shares of common stock beneficially owned by the Reporting Person. F3 · balance_after: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and are beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 20:26 UTC | Opus Genetics, Inc. IRD · Entity 5892 | SaleCommon Stock | 7,842 | $5.18 | $40,657.63 |
DisclosureSEC source: 0000905148-26-001862 · form4.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 592,158 F1 · kind: The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person. F2 · price: The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $5.1828 to $5.1901, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 22, 2026 Filed Jan 27, 2026 00:45 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-000354 · form4.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 F1 · shares: Represents a grant of restricted stock units which vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen (16) quarters, subject to the Reporting Person's continuing service. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:45 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 283 | $9.14 | $2,586.62 |
DisclosureSEC source: 0001104659-25-122576 · tm2533899-1_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,678 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| September 16, 2025 Filed Sep 18, 2025 22:14 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 281 | $9.99 | $2,807.19 |
DisclosureSEC source: 0001104659-25-091361 · tm2526484-2_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,961 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 22:03 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-003320 · form4.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 F1 · shares: Represents a grant of restricted stock units which vest with respect to 25% on September 2, 2026, with the remaining shares vesting in equal monthly installments on the last day of each full month over the next thirty-six (36) months, subject to the Reporting Person's continuing service. Read SEC document |
| September 02, 2025 Filed Sep 11, 2025 22:03 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0000905148-25-003320 · form4.xml · derivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2035-09-01 F2 · derivative.exercise_date: The option will vest with respect to 25% on September 2, 2026, with the remaining shares vesting in equal monthly installments on the last day of each full month over the next thirty-six (36) months, subject to the Reporting Person's continuing service. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:32 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 110,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-069048 · tm2521202-2_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 F1 · shares: Represents an award of 110,000 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after July 16, 2025, immediately prior to the commencement of such meeting, and (ii) July 16, 2026. Read SEC document |
| June 16, 2025 Filed Jun 20, 2025 15:22 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 284 | $5.65 | $1,604.60 |
DisclosureSEC source: 0001104659-25-061040 · tm2518337-2_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,242 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 21:01 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantNon-Employee Stock Option · Derivative | 62,894 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001641172-25-014098 · ownership.xml · derivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,894 Underlying: Common Stock · 62,894 shares Expires 2035-06-04 F1 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests in four equal quarterly installments. Read SEC document |
| May 22, 2025 Filed May 27, 2025 21:45 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $7.48 | $0.00 |
DisclosureSEC source: 0001104659-25-053097 · tm2516118-5_4seq1.xml · derivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2035-05-22 F2 · derivative.exercise_date: The stock option vests in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2025 to April, 2026 and the last installment shall vest on the earlier of (i) the day before the 2026 Annual Meeting of Stockholders is held or (ii) May 31, 2026, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| May 22, 2025 Filed May 27, 2025 21:45 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-053097 · tm2516118-5_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,526 F1 · shares: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2025 to April, 2026 and the last installment shall vest on the earlier of (i) the day before the 2026 Annual Meeting of Stockholders is held or (ii) May 31, 2026, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:47 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 284 | $6.95 | $1,973.80 |
DisclosureSEC source: 0001104659-25-025610 · tm259809-2_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,193 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 21:32 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 130 | $4.37 | $568.10 |
DisclosureSEC source: 0001104659-24-130849 · tm2431760-3_4seq1.xml · nonDerivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,477 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| December 16, 2024 Filed Dec 20, 2024 21:32 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 285 | $4.54 | $1,293.90 |
DisclosureSEC source: 0001104659-24-130849 · tm2431760-3_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,607 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 22:01 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 131 | $2.79 | $365.49 |
DisclosureSEC source: 0001104659-24-101766 · tm2424483-3_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,892 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| September 17, 2024 Filed Sep 20, 2024 01:31 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantNon- Employee Stock Option · Derivative | 30,713 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001493152-24-037220 · ownership.xml · derivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,713 Underlying: Common Stock · 30,713 shares Expires 2034-09-17 F1 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable quarterly through the date of the next annual meeting of stockholders of the Company. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 20:30 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 287 | $2.80 | $803.60 |
DisclosureSEC source: 0001104659-24-100989 · tm2424302-3_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,023 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 00:29 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 131 | $3.21 | $420.51 |
DisclosureSEC source: 0001104659-24-073605 · tm2417704-3_4seq1.xml · nonDerivative · entry 3 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,310 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units ("RSUs"). Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 00:29 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001104659-24-073605 · tm2417704-3_4seq1.xml · derivative · entry 4 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-06-18 F3 · derivative.exercise_date: The stock option vests in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2024 to April, 2025 and the last installment shall vest on the earlier of (i) the day before the 2025 Annual Meeting of Stockholders is held or (ii) May 31, 2025, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 00:29 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-073605 · tm2417704-3_4seq1.xml · nonDerivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,441 F2 · shares: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2024 to April, 2025 and the last installment shall vest on the earlier of (i) the day before the 2025 Annual Meeting of Stockholders is held or (ii) May 31, 2025, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| June 17, 2024 Filed Jun 21, 2024 00:29 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 283 | $3.49 | $987.67 |
DisclosureSEC source: 0001104659-24-073605 · tm2417704-3_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,108 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units ("RSUs"). Read SEC document |
| March 19, 2024 Filed Mar 20, 2024 21:36 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 130 | $10.38 | $1,349.40 |
DisclosureSEC source: 0001104659-24-036792 · tm249354-3_4seq1.xml · nonDerivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,391 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 21:36 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 283 | $10.71 | $3,030.93 |
DisclosureSEC source: 0001104659-24-036792 · tm249354-3_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,521 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 21:00 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 9,204 | $13.70 | $126,094.80 |
DisclosureSEC source: 0001104659-24-011598 · tm245463-1_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,804 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $13.50 through $13.97, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 21:00 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 9,204 | $10.95 | $100,783.80 |
DisclosureSEC source: 0001104659-24-004453 · tm243349-1_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,008 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Table I Column 4. is a weighted average price. These shares were sold in multiple transactions ranging from $10.75 through $11.05, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 22:17 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantNon-Employee Stock Option · Derivative | 8.006 | $0.00 Strike: $4.68 | $0.00 |
DisclosureSEC source: 0001493152-24-001971 · ownership.xml · derivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,015 Underlying: Common Stock · 8,006 shares Expires 2034-01-08 F2 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, 2,003 options are immediately exercisable with the remaining 6,003 options vesting and becoming exercisable in three equal installments on 3/12/2024, 6/12/2024, and 9/12/2024. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 22:17 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantNon-Employee Stock Option · Derivative | 9 | $0.00 Strike: $4.68 | $0.00 |
DisclosureSEC source: 0001493152-24-001971 · ownership.xml · derivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9 Underlying: Common Stock · 9 shares Expires 2034-01-08 F1 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable on the date of the next annual meeting of the stockholders of the Company following the grant date. Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 21:03 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 130 | $7.73 | $1,004.90 |
DisclosureSEC source: 0001104659-23-127726 · tm2333364-3_4seq1.xml · nonDerivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,212 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 21:03 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 284 | $7.64 | $2,169.76 |
DisclosureSEC source: 0001104659-23-127726 · tm2333364-3_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,342 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 20:15 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 130 | $9.84 | $1,279.20 |
DisclosureSEC source: 0001104659-23-102298 · tm2326467-2_4seq1.xml · nonDerivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,626 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 20:15 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 278 | $9.91 | $2,754.98 |
DisclosureSEC source: 0001104659-23-102298 · tm2326467-2_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,756 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 20:24 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 130 | $10.30 | $1,339.00 |
DisclosureSEC source: 0001104659-23-073362 · tm2319280-2_4seq1.xml · nonDerivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,034 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:24 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 283 | $9.92 | $2,807.36 |
DisclosureSEC source: 0001104659-23-073362 · tm2319280-2_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,164 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:32 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001104659-23-061419 · tm2315836-4_4seq1.xml · derivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2033-05-15 F1 · derivative.exercise_date: The stock option vests in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2023 to April, 2024 and the last installment shall vest on the earlier of (i) the day before the 2024 Annual Meeting of Stockholders is held or (ii) May 31, 2024, provided that the Reporting Person continues to serve as a director of the Company on each such vesting date. Read SEC document |
| March 20, 2023 Filed Mar 20, 2023 20:59 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 1,664 | $0.43 | $715.52 |
DisclosureSEC source: 0001104659-23-034515 · tm239927-3_4seq1.xml · nonDerivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 569,399 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 20:59 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 3,654 | $0.40 | $1,461.60 |
DisclosureSEC source: 0001104659-23-034515 · tm239927-3_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 571,063 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| December 19, 2022 Filed Dec 20, 2022 21:09 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 1,429 | $0.37 | $528.73 |
DisclosureSEC source: 0001104659-22-128640 · tm2233121-2_4seq1.xml · nonDerivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 574,717 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 21:09 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 12,408 | $0.40 | $4,963.20 |
DisclosureSEC source: 0001104659-22-128640 · tm2233121-2_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 576,146 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 22:24 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 153,938 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001104659-22-127430 · tm2232815-2_4seq1.xml · derivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,938 Underlying: Common Stock · 153,938 shares Expires 2032-12-13 F1 · derivative.exercise_date: -125,000 of the stock options vest in twelve equal quarterly installments beginning each three successive month period following December 13, 2022 (the "Option Grant Date") until the third anniversary of the Option Grant Date (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest). 28,938 of the stock options vest in six equal month installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) beginning on the on the last day of each month over a period from December, 2022 to May, 2023. The options vest provided the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:06 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 1,348 | $1.13 | $1,523.24 |
DisclosureSEC source: 0001104659-22-101924 · tm2226273-1_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,554 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 21, 2022 Filed Jun 22, 2022 20:05 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 1,351 | $1.14 | $1,540.14 |
DisclosureSEC source: 0001104659-22-073482 · tm2219034-1_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 589,902 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| May 16, 2022 Filed May 17, 2022 20:05 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 16,627 | $1.03 | $17,125.81 |
DisclosureSEC source: 0001104659-22-061934 · tm2215781-1_4seq1.xml · nonDerivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 591,253 F2 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| May 14, 2022 Filed May 17, 2022 20:05 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-061934 · tm2215781-1_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 607,880 F1 · shares: Represents performance-based restricted stock units ("PRSUs") granted to the Reporting Person on June 24, 2021 under the Issuer's 2021 Equity Incentive Plan. Each PRSU represents the right to receive one share of Common Stock. On May 14, 2022 the Compensation Committee of the Issuer's Board of Directors certified that the PRSUs' performance criteria had been satisfied and the PRSUs vested in full. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:01 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 1,409 | $1.27 | $1,789.43 |
DisclosureSEC source: 0001104659-22-037005 · tm2210137-1_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 557,880 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:02 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 19,612 | $2.05 | $40,204.60 |
DisclosureSEC source: 0001104659-22-001449 · tm221611-2_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 559,289 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 21:01 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 5,497 | $2.27 | $12,478.19 |
DisclosureSEC source: 0001104659-21-152596 · tm2136040-1_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 578,901 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.